Clinical

Dataset Information

Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome


ABSTRACT: This randomized phase Ib trial studies the side effects and best dose of naproxen in preventing deoxyribonucleic acid (DNA) mismatch repair deficient colorectal cancer in patients with Lynch syndrome. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of naproxen may keep cancer from forming in patients with Lynch syndrome.

DISEASE(S): Lynch Syndrome,Colorectal Neoplasms, Hereditary Nonpolyposis

PROVIDER: 2160055 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR